Search Results - "Lehrer, Douglas"

Refine Results
  1. 1

    Daily oral dosing of vitamin D3 using 5000 TO 50,000 international units a day in long-term hospitalized patients: Insights from a seven year experience by McCullough, Patrick J., Lehrer, Douglas S., Amend, Jeffrey

    “…•Daily dosing with vitamin D ranged from 5000 IU/day to 50,000 IU/day.•No cases of hypercalcemia observed using these doses of vitamin D for up to 7 years.•The…”
    Get full text
    Journal Article
  2. 2

    Vitamin D, cod liver oil, sunshine, and phototherapy: Safe, effective and forgotten tools for treating and curing tuberculosis infections — A comprehensive review by McCullough, Patrick J., Lehrer, Douglas S.

    “…•TB is a major public health problem, affecting one third of the world’s population.•Vitamin D deficiency is common in patients infected with TB throughout the…”
    Get full text
    Journal Article
  3. 3

    Psychiatric Comorbidities and Schizophrenia by Buckley, Peter F., Miller, Brian J., Lehrer, Douglas S., Castle, David J.

    Published in Schizophrenia bulletin (01-03-2009)
    “…Psychiatric comorbidities are common among patients with schizophrenia. Substance abuse comorbidity predominates. Anxiety and depressive symptoms are also very…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Comparing Global Assessment of Functioning (GAF) and World Health Organization Disability Assessment Schedule (WHODAS) 2.0 in schizophrenia by Gspandl, Scott, Peirson, Ryan P., Nahhas, Ramzi W., Skale, Tracey Goodman, Lehrer, Douglas S.

    Published in Psychiatry research (01-01-2018)
    “…WHODAS-2.0 is a suggested replacement to the GAF in DSM-5. This study's purpose was to assess their comparative correlation in adults with schizophrenia…”
    Get full text
    Journal Article
  6. 6
  7. 7

    D2/D3 dopamine receptor binding with [F-18]fallypride correlates of executive function in medication-naïve patients with schizophrenia by Vyas, Nora S, Buchsbaum, Monte S, Lehrer, Douglas S, Merrill, Brian M, DeCastro, Alex, Doninger, Nicholas A, Christian, Bradley T, Mukherjee, Jogeshwar

    Published in Schizophrenia research (01-02-2018)
    “…Abstract Converging evidence indicates that the prefrontal cortex is critically involved in executive control and that executive dysfunction is implicated in…”
    Get full text
    Journal Article
  8. 8

    Reading abilities and dopamine D 2 /D 3 receptor availability: An inverted U-shaped association in subjects with schizophrenia by Mitelman, Serge A, Buchsbaum, Monte S, Vyas, Nora S, Christian, Bradley T, Merrill, Brian M, Buchsbaum, Bradley R, Mitelman, Alexis M, Mukherjee, Jogeshwar, Lehrer, Douglas S

    Published in Brain and language (01-12-2021)
    “…Reading impairments are prominent trait-like features of cognitive deficits in schizophrenia, predictive of overall cognitive functioning and presumably linked…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications by McCullough, Patrick J, McCullough, William P, Lehrer, Douglas, Travers, Jeffrey B, Repas, Steven J

    Published in Nutrients (29-04-2021)
    “…Vitamin D, sunshine and UVB phototherapy were first reported in the early 1900s to control psoriasis, cure rickets and cure tuberculosis (TB). Vitamin D also…”
    Get full text
    Journal Article
  11. 11

    Anosognosia in schizophrenia: hidden in plain sight by Lehrer, Douglas S, Lorenz, Jennifer

    Published in Innovations in clinical neuroscience (01-05-2014)
    “…Poor insight is a cardinal symptom of schizophrenia that, while not universally and uniformly expressed in all patients, is among the most common of its…”
    Get full text
    Journal Article
  12. 12

    Relationship between white matter glucose metabolism and fractional anisotropy in healthy and schizophrenia subjects by Mitelman, Serge A., Buchsbaum, Monte S., Christian, Bradley T., Merrill, Brian M., Adineh, Mehdi, DeCastro, Alex, Buchsbaum, Bradley R., Lehrer, Douglas S.

    Published in Psychiatry research. Neuroimaging (30-05-2020)
    “…Decreased fractional anisotropy and increased glucose utilization in the white matter have been reported in schizophrenia. These findings may be indicative of…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia by Buchsbaum, Monte S., Christian, Bradley T., Lehrer, Douglas S., Narayanan, Tanjore K., Shi, Bingzhi, Mantil, Joseph, Kemether, Eileen, Oakes, Terrence R., Mukherjee, Jogeshwar

    Published in Schizophrenia research (01-07-2006)
    “…Abnormalities in the dopaminergic system are implicated in schizophrenia. [F-18]fallypride is a highly selective, high affinity PET ligand well suited for…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task by Christian, Bradley T., Lehrer, Douglas S., Shi, Bingzhi, Narayanan, Tanjore K., Strohmeyer, Pamela S., Buchsbaum, Monte S., Mantil, Joseph C.

    Published in NeuroImage (Orlando, Fla.) (15-05-2006)
    “…We used the highly selective D2/D3 dopamine PET radioligand [F-18]fallypride to demonstrate that cognitive task induced dopamine release can be measured in the…”
    Get full text
    Journal Article